anonymous
Guest
anonymous
Guest
. Prandin, LevemirYet another failed launch attempt by bozo nordisk. Just add it to the list…rybelsus, tresiba, xultophy, wegovy. Any others?
. Prandin, LevemirYet another failed launch attempt by bozo nordisk. Just add it to the list…rybelsus, tresiba, xultophy, wegovy. Any others?
I would disagree with that. Fiasp and Xultophy are truly innovative products that didn't catch on with insurers and primary care providers in the US. We have several more products that we won't launch because of the dysfunctional HC system in the states. Look at the success of Soliqua, a completely inferior product. We handed that to Sanofi.Fiasp